Reactive oxygen species (ROS) are recognized for having an impact in enabling pathophysiological signal transmission. An imbalance between the body’s oxidative and anti-oxidative systems leads to overproduction of ROS, a condition termed oxidative stress. It contributes to the development of several diseases linked to metabolic inflammation. Efforts to leverage ROS research for clinical benefit have faced significant hurdles, notably the lack of therapeutic specificity, altered physiological ROS signaling, and consistent failures of systemic, broad-spectrum antioxidant therapies. Despite these enormous challenges, there is an evolutionary shift emerging in the area, moving away from ROS scavenging and toward a more complex and precise control of redox equilibrium. Emerging opportunities are propelled by enhanced understanding of ROS biology, enabling nanocarriers for targeted drug release at sites of pathological ROS elevation, which exploit the variability and compartmentalization of ROS production. Addressing the substantial translational gaps especially in the generation of reliable, real-time biomarkers and improving the efficiency of preclinical models is essential. The ultimate goal is to achieve targeted therapies that restore redox homeostasis, thereby considerably improving outcomes for patients afflicted by metabolic inflammation.